Fennec Pharmaceuticals Inc. (FENC) AI Stock Analysis

Fennec Pharmaceuticals Inc. is a biopharmaceutical company specializing in the development of innovative therapies. At the forefront of its clinical pipeline is PEDMARK, a formulation of sodium thiosulfate designed to prevent platinum-induced ototoxicity in pediatric cancer patients. The product candidate addresses critical side effects associated with platinum-based chemotherapy. Originally known as Adherex Technologies Inc., the company rebranded as Fennec Pharmaceuticals Inc. in September 2014. Founded in 1996 and based in Research Triangle Park, North Carolina, Fennec leverages strategic partnerships and scientific expertise to drive the development and commercialization of PEDMARK.

Revenue expanded rapidly from $170,000 in FY2021 to $47.5M in FY2024, before declining 6.1% to $44.6M in FY2025. Gross margin has remained high, recorded at 91.6% in FY2025. Operating margin was -14.2% and net income was -$9.7M in FY2025, down from an operating margin of 5.2% and net income of -$436,000 in FY2024. For the latest quarter ended June 30, 2026, quarterly revenue grew 85.2% year-over-year, lifting trailing twelve months revenue to $59.2M and operating margin to 9.7%, alongside an EPS of -$0.12.

As of June 30, 2026, Fennec Pharmaceuticals held $41.2M in cash and short-term investments, with total assets of $75.8M and shareholders' equity of $42.4M. The company shows a current ratio of 5.85. Operating cash flow and free cash flow turned negative to -$12.5M in FY2025, after generating $27.0M in FY2024. Over a 5-year period, the share count increased by 40.1%.

At a last close of $9.98 on October 16, 2026, Fennec Pharmaceuticals has a market cap of $350.0M and an enterprise value of $344.6M. Its forward P/E ratio stands at 10.6x, compared to 17.3x for the median of its US-listed Healthcare peers. Its price-to-sales multiple is 5.9x versus the peer median of 4.1x, and its EV-to-EBITDA ratio of 20.3x sits above the peer median of 12.0x. Over the past year, FENC shares gained 15.5%, slightly lagging the S&P 500 (SPY) return of 16.8%, while its 5-year return of 8.6% trailed the index's 83.0% gain.

Consensus ratings include 4 Strong Buy, 2 Buy, and zero Hold, Sell, or Strong Sell recommendations. The mean price target is $17.67, representing a 77.0% upside versus the last close of $9.98. For the fiscal year ending December 31, 2026, analysts estimate revenue of $72.6M and EPS of $0.32, implying 213.9% EPS growth. In FY2027, 5 analysts project revenue of $103.1M and EPS of $0.95. The company beat EPS estimates in 1 of the last 4 quarters, with the next earnings date scheduled for November 12, 2026.

This page is an AI-written research summary of Fennec Pharmaceuticals Inc. (FENC). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: FENC income statement, FENC balance sheet, FENC key metrics, FENC analyst forecast, FENC chart. See the FENC stock overview for the latest quote and news.